ABUS Straddle Strategy
ABUS (Arbutus Biopharma Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
ABUS (Arbutus Biopharma Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $848.8M, a trailing P/E of 5.20, a beta of 0.62 versus the broader market, a 52-week range of 2.94-5.1, average daily share volume of 2.2M, a public-listing history dating back to 2007, approximately 44 full-time employees. These structural characteristics shape how ABUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.62 indicates ABUS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 5.20 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a straddle on ABUS?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current ABUS snapshot
As of May 15, 2026, spot at $4.25, ATM IV 405.20%, IV rank 100.00%, expected move 116.17%. The straddle on ABUS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on ABUS specifically: ABUS IV at 405.20% is rich versus its 1-year range, which makes a premium-buying ABUS straddle relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 116.17% (roughly $4.94 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABUS should anchor to the underlying notional of $4.25 per share and to the trader's directional view on ABUS stock.
ABUS straddle setup
The ABUS straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABUS near $4.25, the first option leg uses a $4.25 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABUS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABUS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.25 | N/A |
| Buy 1 | Put | $4.25 | N/A |
ABUS straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
ABUS straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on ABUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on ABUS
Straddles on ABUS are pure-volatility plays that profit from large moves in either direction; traders typically buy ABUS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
ABUS thesis for this straddle
The market-implied 1-standard-deviation range for ABUS extends from approximately $-0.69 on the downside to $9.19 on the upside. A ABUS long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ABUS IV rank near 100.00% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on ABUS at 405.20%. As a Healthcare name, ABUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABUS-specific events.
ABUS straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABUS alongside the broader basket even when ABUS-specific fundamentals are unchanged. Always rebuild the position from current ABUS chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on ABUS?
- A straddle on ABUS is the straddle strategy applied to ABUS (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ABUS stock trading near $4.25, the strikes shown on this page are snapped to the nearest listed ABUS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABUS straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ABUS straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 405.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABUS straddle?
- The breakeven for the ABUS straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABUS market-implied 1-standard-deviation expected move is approximately 116.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on ABUS?
- Straddles on ABUS are pure-volatility plays that profit from large moves in either direction; traders typically buy ABUS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current ABUS implied volatility affect this straddle?
- ABUS ATM IV is at 405.20% with IV rank near 100.00%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.